background
surveil
winter
respiratori
viral
ill
carri
nearli
year
use
clinic
diagnosi
gener
practition
part
scottish
sentinel
gener
practic
ssgp
network
contemparan
laboratori
diagnosi
avail
previous
object
assess
proport
influenzalik
ill
ili
attribut
influenza
respiratori
syncyti
viru
rsv
picornaviru
infect
winter
season
compar
influenza
pcr
data
serolog
pair
blood
sampl
studi
design
combin
nose
throat
swab
patient
ili
attend
gener
practic
across
scotland
submit
laboratori
viru
pcr
sampl
solut
vpss
extract
nucleic
acid
test
use
multiplex
reversetranscript
polymeras
chain
reaction
rtpcr
assay
serolog
analysi
perform
pair
serum
sampl
use
complement
fixat
assay
rate
influenza
viru
posit
compar
report
ili
obtain
ssgp
network
result
sampl
receiv
laboratori
pcr
posit
influenza
viru
nine
picornaviru
three
rsv
pcr
posit
two
dual
influenza
apicornaviru
infect
nineti
four
neg
virus
test
result
pair
sera
patient
show
rise
titr
influenza
pcr
posit
sampl
one
pcr
neg
patient
display
signific
rise
titr
influenza
virolog
data
parallel
ssgp
data
avail
least
week
earlier
conclus
influenza
infect
detect
major
patient
ili
picornaviru
infect
also
shown
import
caus
ill
pcr
rapid
sensit
method
respiratori
viru
surveil
serolog
slow
insensit
difficult
interpret
low
titr
influenza
viru
infect
import
caus
respiratori
infect
popul
winter
season
makela
et
al
nicolson
et
al
age
group
abbrevi
ssgp
scottish
sentinel
gener
practic
ili
influenzalik
ill
rtpcr
reversetranscript
polymeras
chain
reaction
vpss
viral
pcr
sampl
solut
cft
complement
fixat
test
affect
influenza
infect
seriou
complic
occur
much
frequent
young
children
elderli
year
old
sczuc
young
children
influenza
infect
lead
significantli
increas
antibiot
prescript
outpati
visit
hospitalis
neuzil
et
al
elderli
nurs
home
patient
cultur
proven
influenza
b
infect
show
significantli
increas
mortal
drinka
et
al
risk
group
also
suffer
consider
morbid
signific
mortal
neuzil
et
al
nicholson
neuraminidas
inhibitor
class
antiinfluenza
drug
ie
zanamivir
oseltamivir
fiddian
effect
administ
earli
infect
modernis
monitor
commun
influenza
outbreak
requir
rapid
diagnosi
influenza
requir
enabl
earli
treatment
reversetranscript
polymeras
chain
reaction
rtpcr
sensit
specif
method
detect
influenza
infect
viru
isol
direct
immunofluoresc
use
rapid
diagnosi
magnard
et
al
pregliasco
et
al
stockton
et
al
wallac
et
al
data
unpublish
demonstr
rtpcr
detect
twice
mani
influenza
posit
sampl
viru
cultur
direct
immunofluoresc
combin
multiplex
pcr
use
monitor
influenza
outbreak
england
wale
elli
et
al
respiratori
syncyti
viru
rsv
shown
signific
caus
influenzalik
ill
ili
wide
age
rang
patient
winter
respiratori
season
zambon
et
al
therefor
essenti
make
virolog
diagnosi
effect
appropri
treatment
pilot
studi
perform
influenza
season
rtpcr
influenza
b
optimis
wallac
et
al
use
monitor
commun
influenza
outbreak
scotland
pcr
result
avail
within
h
sampl
arriv
laboratori
carman
et
al
paper
report
extens
virolog
surveil
includ
detect
respiratori
syncyti
viru
picornaviru
infect
patient
report
influenzalik
ill
gener
practic
scotland
season
patient
present
influenzalik
ill
gener
practic
across
scotland
octob
march
ask
provid
throat
swab
high
nasal
swab
swab
swirl
vigor
singl
vial
contain
ml
guanidiniumbas
lysi
buffer
viru
pcr
sampl
solut
vpss
provid
high
pure
viral
rna
extract
kit
tm
roch
diagnost
gmbh
penzberg
germani
swab
discard
use
vpss
sampl
post
laboratori
blood
sampl
serolog
analysi
taken
present
least
week
later
rang
day
mean
day
consent
patient
two
site
fort
william
dingwal
total
combin
swab
sampl
pair
blood
sampl
receiv
clinic
protocol
approv
relev
local
area
medic
ethic
committe
multiplex
rtpcr
perform
identifi
influenza
b
respiratori
syncyti
viru
picornaviru
rna
extract
sampl
use
adapt
protocol
high
pure
viral
rna
extract
kit
tm
roch
diagnost
gmbh
penzberg
germani
l
vpss
sampl
load
directli
onto
spincolumn
manufactur
instruct
follow
rna
elut
volum
l
cdna
synthesis
reversetranscript
previous
describ
wallac
et
al
nest
pcr
perform
use
primer
amplifi
region
within
gene
influenza
matrix
protein
zhang
evan
ii
influenza
b
haemagglutinin
stockton
et
al
iii
n
p
region
rsv
genom
stockton
et
al
fi
subunit
fusion
f
glycoprotein
henkel
et
al
iv
picornaviru
ncr
andeweg
et
al
taqstart
tm
antibodi
clontech
palo
alto
usa
use
increas
sensit
product
specif
round
pcr
wallac
et
al
cdna
l
amplifi
reaction
volum
l
contain
four
primer
pair
pmoll
mm
mgcl
pcr
perform
thin
wall
ml
tube
thermal
cycler
pe
appli
biosystem
warrington
cheshir
uk
initi
denatur
step
c
cycl
c
c
c
follow
final
extens
min
c
second
round
amplif
perform
use
increas
anneal
temperatur
c
nest
primer
pmoll
final
volum
l
contain
l
first
round
product
pcr
product
analys
nusiev
agaros
fmc
bioproduct
usa
gel
contain
gml
ethidium
bromid
product
size
bp
expect
influenza
b
influenza
rsv
picornaviru
rsv
b
respect
specif
complement
fixat
assay
detect
elev
antibodi
titr
consist
influenza
influenza
b
viru
infect
perform
pair
serum
sampl
patient
fort
william
dingwal
practic
fourfold
rise
antibodi
titr
second
sampl
test
parallel
first
defin
signific
diagnost
current
recent
infect
influenza
b
first
sampl
taken
late
day
sinc
onset
titr
greater
also
consid
signific
total
swab
sampl
receiv
patient
age
year
mean
year
femal
male
smoker
defin
risk
accord
uk
nation
guidelin
influenza
vaccin
forti
three
patient
receiv
influenza
vaccin
sampl
taken
day
perceiv
onset
ili
mean
day
sampl
taken
within
day
rel
proport
sampl
taken
week
correl
well
figur
scottish
sentinel
gp
network
fig
sampl
collect
pcr
posit
influenza
picornaviru
pcr
posit
sampl
rsv
pcr
posit
sampl
pcr
posit
influenza
picornaviru
neg
four
virus
influenza
b
viru
detect
pcr
studi
popul
rate
influenza
pcr
posit
studi
fell
significantli
sampl
taken
longer
onset
ili
day
day
day
fig
total
pair
blood
sampl
obtain
influenza
ab
complement
fixat
test
cft
fiftyseven
blood
sampl
match
throatnos
swab
sampl
pcr
posit
influenza
fourtyeight
influenza
posit
patient
display
signific
fourfold
greater
increas
antibodi
titr
influenza
viru
cft
tabl
nine
remain
influenza
pcr
posit
patient
two
static
high
titr
influenza
viru
tabl
footnot
h
n
five
display
twofold
rise
cft
titr
tabl
footnot
c
j
two
vaccin
fall
titr
tabl
footnot
l
influenza
pcr
neg
sampl
match
serolog
sampl
show
evid
influenza
infect
cft
titr
second
sampl
lower
signific
increas
titr
sampl
one
pcr
neg
patient
display
increas
cft
titr
influenza
consist
recent
infect
tabl
footnot
b
swab
sampl
patient
taken
day
sinc
onset
symptom
eleven
patient
rais
titr
sampl
three
show
less
signific
twofold
rise
titr
remain
eight
patient
static
fall
titr
twofold
rise
note
three
patient
whose
swab
sampl
taken
previous
demonstr
influenza
pcr
rapid
sensit
user
friendli
assay
wallac
et
al
expand
capabl
rtpcr
assay
includ
rsv
picornaviru
infect
addit
influenza
b
virus
employ
assay
rapid
test
monitor
circul
respiratori
virus
commun
improv
previous
report
capac
provid
realtim
surveil
inform
public
health
polici
maker
confirm
practic
altern
nucleic
acid
test
cours
winter
season
major
patient
report
gp
diagnos
ili
infect
influenza
viru
peak
influenza
season
week
inclus
fig
proport
patient
influenza
pcr
posit
rose
sampl
posit
week
picornaviru
infect
caus
respiratori
ill
patient
report
gp
ili
winter
season
fail
detect
influenza
b
infect
studi
popul
lack
sensit
influenza
b
detect
one
set
sampl
receiv
laboratori
separ
studi
take
place
england
initi
studi
sampl
rsv
pcr
neg
although
clear
rsv
diagnos
greater
sensit
either
viru
cultur
direct
immunofluoresc
throughout
season
routin
diagnost
sampl
data
shown
howev
differ
set
rsv
primer
introduc
laboratori
studi
complet
three
remain
store
neg
sampl
retest
posit
rsv
therefor
nearli
sampl
posit
one
virus
test
noteworthi
sampl
taken
within
day
onset
symptom
influenza
posit
decreas
posit
sampl
taken
day
viral
nucleic
acid
may
longer
present
proport
patient
present
later
cours
infect
sever
symptom
influenza
infect
may
encourag
patient
actual
influenza
infect
report
gp
earlier
patient
influenza
infect
rate
sampl
studi
depend
patient
feel
ill
report
gp
number
influenza
posit
sampl
correl
report
ili
per
popul
gp
sentinel
practic
collat
scieh
howev
result
avail
within
h
least
week
earlier
publish
surveil
figur
abl
monitor
commun
influenza
infect
especi
c
sampl
taken
day
day
sinc
vaccin
subject
day
sinc
onset
respect
sampl
taken
day
sinc
vaccin
subject
day
sinc
onset
viral
nucleic
acid
may
longer
present
day
e
sampl
taken
day
sinc
onset
viral
nucleic
acid
may
longer
present
f
sampl
taken
day
sinc
onset
viral
nucleic
acid
may
longer
present
day
g
sampl
taken
day
sinc
onset
h
sampl
taken
day
sinc
onset
antibodi
may
risen
alreadi
first
sampl
sampl
taken
day
sinc
onset
j
sampl
taken
day
sinc
onset
respect
antibodi
may
risen
alreadi
first
sampl
k
sampl
taken
day
sinc
onset
viral
nucleic
acid
may
longer
present
day
l
sampl
taken
day
sinc
onset
vaccin
subject
second
sampl
patient
present
gp
twice
initi
sampl
pcr
serolog
posit
influenza
infect
n
sampl
taken
day
sinc
onset
symptom
antibodi
may
risen
alreadi
first
sampl
sampl
taken
day
sinc
onset
viral
nucleic
acid
may
longer
present
day
import
circul
nonvaccin
strain
commun
add
extra
burden
health
care
provid
also
addit
inform
caus
ill
avail
multiplex
pcr
perform
picornaviru
infect
identifi
caus
around
influenzalik
ill
season
proport
patient
present
ili
influenza
infect
patient
influenza
pcr
neg
even
height
influenza
season
communitybas
studi
zambon
et
al
shown
rsv
import
caus
ili
age
group
howev
found
sampl
group
studi
pcr
assay
develop
respiratori
pathogen
includ
parainfluenza
coronaviru
includ
viru
relat
sever
acut
respiratori
syndrom
sar
drosten
et
al
human
metapneumoviru
van
den
hoogen
et
al
mycoplasma
chlamydia
speci
assess
contribut
agent
commun
influenzalik
ill
one
disadvantag
use
pcr
alon
monitor
commun
influenza
outbreak
lack
viabl
viru
cultur
epidemiolog
analysi
although
pcr
use
limit
extent
subtyp
influenza
viru
eg
use
heamagglutininspecif
primer
proport
sampl
continu
submit
manner
facilit
detail
analysi
surveil
sampl
submit
vpss
guanidiumbas
buffer
use
first
phase
rna
extract
previou
studi
shown
increas
posit
rate
detect
rna
virus
carman
et
al
ideal
post
sampl
laboratori
requir
live
viru
serolog
result
difficult
interpret
even
difficult
match
pcr
result
one
sampl
posit
serolog
pcr
neg
sampl
taken
day
sinc
onset
symptom
decreas
sensit
detect
note
fig
fig
also
show
sampl
pcr
posit
day
onset
reflect
either
good
qualiti
sampl
longer
perceiv
length
ill
nine
nondiagnost
serolog
result
influenza
pcr
posit
patient
analysi
nine
influenza
pcr
posit
patient
show
five
includ
one
vaccin
first
sampl
taken
day
sinc
onset
tabl
footnot
h
j
l
n
titr
first
sampl
may
explain
lack
signific
rise
pcr
neg
patient
suggest
serolog
result
initi
titr
six
patient
higher
background
serolog
titr
greater
equal
report
gp
day
onset
symptom
three
show
twofold
rise
may
pcr
posit
sampl
earlier
cours
infect
three
patient
tabl
footnot
g
sampl
earli
infect
two
titr
fall
static
pcr
evid
influenza
infect
patient
elev
cft
titr
may
due
infect
previou
year
asymptomat
infect
earlier
season
except
two
case
tabl
footnot
initi
titr
pcr
neg
group
low
practic
consid
diagnost
infect
even
sampl
day
addit
second
serum
major
sampl
pcr
serolog
posit
would
consid
diagnost
infect
unless
part
pair
although
titr
consid
diagnost
mani
virolog
laboratori
pcr
posit
sampl
achiev
level
higher
addit
patient
titr
titr
second
convalesc
sampl
twentyon
pcr
neg
patient
titr
less
may
influenza
season
titr
perhap
even
consid
indic
recent
infect
difficulti
interpret
serolog
result
meaning
led
us
favour
pcr
frontlin
assay
serolog
result
obtain
suggest
patient
pcr
neg
infect
influenza
viru
support
hypothesi
true
influenza
infect
encourag
earlier
present
gp
surgeri
conclus
differenti
diagnosi
influenza
serolog
method
requir
two
blood
sampl
week
result
show
alway
easi
interpret
blood
sampl
inappropri
sampl
take
patient
acut
respiratori
ill
howev
increas
use
nose
throat
swab
gp
set
rapid
pcr
result
turnaround
time
allow
virus
contribut
annual
winter
respiratori
season
monitor
time
use
manner
develop
set
multiplex
pcr
achiev
futur
surveil
diagnosi
respiratori
viral
infect
